For the reason that people who carry the APOE e4 gene variant appear to have a larger danger of serious problems, the FDA suggests currently being tested to the gene variant before beginning treatment with lecanemab or donanemab. The extension analyze also evaluated CLARITY AD members who experienced a delayed https://rolimb086zjt6.vidublog.com/profile